{"bill":{"bill_id":1288231,"change_hash":"7b41e16c61e433b0de93af890aea7781","session_id":1658,"session":{"session_id":1658,"state_id":52,"year_start":2019,"year_end":2020,"prefile":0,"sine_die":1,"prior":1,"special":0,"session_tag":"Regular Session","session_title":"2019-2020 Regular Session","session_name":"116th Congress"},"url":"https:\/\/legiscan.com\/US\/bill\/HB5402\/2019","state_link":"https:\/\/www.congress.gov\/bill\/116th-congress\/house-bill\/5402\/all-info","completed":0,"status":1,"status_date":"2019-12-11","progress":[{"date":"2019-12-11","event":1},{"date":"2019-12-11","event":9},{"date":"2019-12-11","event":9},{"date":"2019-12-12","event":9}],"state":"US","state_id":52,"bill_number":"HB5402","bill_type":"B","bill_type_id":"1","body":"H","body_id":114,"current_body":"H","current_body_id":114,"title":"Protecting America\u2019s Life Saving Medicines Act of 2019","description":"Directs the Food and Drug Administration (FDA) to conduct a study on drugs that are currently being tested and are unlikely to be approved, but would, if approved, address an unmet medical need for the treatment of a serious or life threatening disease or condition or a rare disease or condition (high-risk, high-reward drugs). The FDA must submit to the Department of the Treasury a list of such high-risk, high-reward drugs not later than 180 days after the completion of the study. The bill also allows a new tax credit for 25% of the clinical testing expenses for high-risk, high-reward drugs.","pending_committee_id":2355,"committee":{"committee_id":2355,"chamber":"H","chamber_id":114,"name":"Subcommittee on Health"},"referrals":[{"date":"2019-12-11","committee_id":2317,"chamber":"H","chamber_id":114,"name":"Ways And Means"},{"date":"2019-12-12","committee_id":2355,"chamber":"H","chamber_id":114,"name":"Subcommittee on Health"}],"history":[{"date":"2019-12-11","action":"Introduced in House","chamber":"H","chamber_id":114,"importance":0},{"date":"2019-12-11","action":"Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.","chamber":"H","chamber_id":114,"importance":1},{"date":"2019-12-11","action":"Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.","chamber":"H","chamber_id":114,"importance":1},{"date":"2019-12-12","action":"Referred to the Subcommittee on Health.","chamber":"H","chamber_id":114,"importance":1}],"sponsors":[{"people_id":18309,"person_hash":"9dqdbujj","party_id":"1","state_id":52,"party":"D","role_id":1,"role":"Rep","name":"Josh Gottheimer","first_name":"Josh","middle_name":"","last_name":"Gottheimer","suffix":"","nickname":"","district":"HD-NJ-5","ftm_eid":39707518,"votesmart_id":169202,"opensecrets_id":"N00036944","knowwho_pid":346665,"ballotpedia":"Josh_Gottheimer","sponsor_type_id":1,"sponsor_order":1,"committee_sponsor":0,"committee_id":0,"state_federal":0},{"people_id":9334,"person_hash":"ivqb9ymw","party_id":"2","state_id":52,"party":"R","role_id":1,"role":"Rep","name":"Fred Upton","first_name":"Fred","middle_name":"","last_name":"Upton","suffix":"","nickname":"","district":"HD-MI-6","ftm_eid":2001367,"votesmart_id":26906,"opensecrets_id":"N00004133","knowwho_pid":158900,"ballotpedia":"Fred_Upton","sponsor_type_id":2,"sponsor_order":2,"committee_sponsor":0,"committee_id":0,"state_federal":0},{"people_id":18304,"person_hash":"r8ccgqyg","party_id":"2","state_id":52,"party":"R","role_id":1,"role":"Rep","name":"Brian Fitzpatrick","first_name":"Brian","middle_name":"K.","last_name":"Fitzpatrick","suffix":"","nickname":"","district":"HD-PA-8","ftm_eid":39434649,"votesmart_id":167708,"opensecrets_id":"N00038779","knowwho_pid":568624,"ballotpedia":"Brian_Fitzpatrick","sponsor_type_id":2,"sponsor_order":3,"committee_sponsor":0,"committee_id":0,"state_federal":0}],"sasts":[],"subjects":[{"subject_id":13338,"subject_name":"Taxation"},{"subject_id":13593,"subject_name":"Drug safety, medical device, and laboratory regulation"},{"subject_id":81058,"subject_name":"Drug therapy"},{"subject_id":22688,"subject_name":"Government studies and investigations"},{"subject_id":13224,"subject_name":"Income tax credits"},{"subject_id":13241,"subject_name":"Medical research"}],"texts":[{"doc_id":2080754,"date":"2019-12-20","type":"Introduced","type_id":1,"mime":"application\/pdf","mime_id":2,"url":"https:\/\/legiscan.com\/US\/text\/HB5402\/id\/2080754","state_link":"https:\/\/www.congress.gov\/116\/bills\/hr5402\/BILLS-116hr5402ih.pdf","text_size":329606,"text_hash":"2f93ce63310d1667d3feaf66896c77d2"}],"votes":[],"amendments":[],"supplements":[],"calendar":[]}}